経口抗ウイルス薬の世界市場

経口抗ウイルス薬の世界市場は2030年までに390億米ドルに達する見込み

2024年に357億米ドルと推定される経口抗ウイルス薬の世界市場は、2024～2030年の分析期間においてCAGR 1.5%で成長し、2030年には390億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるヒト免疫不全ウイルス適応症は、CAGR 1.0％を記録し、分析期間終了までに180億米ドルに達すると予測されます。肝炎治療薬セグメントの成長率は、分析期間中CAGR 2.1%と推定されます。

米国市場は97億米ドルと推定、中国はCAGR 2.8％で成長予測

米国の経口抗ウイルス薬市場は2024年に97億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに71億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは2.8%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ0.6%と1.2%と予測されています。欧州では、ドイツがCAGR約0.8%で成長すると予測されています。

世界の経口抗ウイルス薬市場- 主要動向と促進要因のまとめ

経口抗ウイルス薬が感染症管理の展望を再構築？

経口抗ウイルス薬-宿主細胞内でのウイルスの複製を阻害する経口投与用の薬剤-は、現代の抗ウイルス療法の要として台頭してきました。医療機関での投与が必要な注射用抗ウイルス薬とは異なり、経口製剤は利便性、拡張性、外来での投与が可能であり、公衆衛生上の危機的状況や慢性的なウイルス性疾患にとって極めて重要です。インフルエンザや肝炎からHIV、ヘルペス、そして最近ではCOVID-19に至るまで、経口抗ウイルス薬は多様なウイルス病原体において臨床的・商業的成功を収めています。

COVID-19のパンデミックは、経口抗ウイルス薬の世界の実験場となり、モルヌピラビルやニルマトルビル／リトナビル（POVID）といった分子が、ウイルス量、入院率、感染リスクの低減のために大規模に展開されました。これらの治療は、パンデミック対策における備蓄、早期介入、コミュニティベースの提供の戦略的重要性を浮き彫りにしました。これらの薬剤の成功は、製薬大手とバイオテクノロジー新興企業の双方に、経口療法による呼吸器、神経栄養、出血性ウイルスを標的とした開発パイプラインの加速を促しています。

なぜ広域スペクトル薬剤と耐性防止機構が求められているのか？

ウイルスの変異が治療効果に絶え間ない課題を投げかけているため、保存されたウイルスの標的に作用する広域スペクトル経口抗ウイルス薬に対する需要が高まっています。ポリメラーゼ阻害剤、プロテアーゼ阻害剤、エントリー阻害剤は、複数の菌株や種に対してクロスウイルス活性を示すように設計されています。このような治療薬は、病原体特異的な診断への依存を減らし、治療レジメンを簡素化します。

抗ウイルス剤耐性のリスクを軽減するために、薬剤開発者は耐性に対する遺伝的障壁の高い薬剤を設計し、選択圧を軽減する併用療法を模索しています。ウイルスの複製に不可欠な宿主の経路に干渉する宿主指向性抗ウイルス薬は、その汎ウイルス性の可能性から支持を集めています。さらに、HIVやHBVのような慢性疾患に対する1日1回の経口投与を可能にする一方で、バイオアベイラビリティ、組織浸透性、治療域を改善するために、プロドラッグ製剤や薬物動態改善剤が使用されています。

技術プラットフォームと市場参入戦略はどのように治療領域を拡大しているのか？

構造に基づく薬剤設計、AIを活用した化合物スクリーニング、ハイスループットなウイルスアッセイの登場により、新規経口抗ウイルス薬候補の同定が加速しています。企業プロファイルは、最適な薬力学と安全性プロファイルを持つ分子を設計するために、機械学習とin silicoモデリングを活用しています。経口抗ウイルス薬はまた、ナノ粒子担体、腸溶性コーティング、徐放性製剤などの固形製剤技術の進歩により、吸収性と患者のコンプライアンスを向上させています。

ボランタリーライセンス、段階的価格設定、官民パートナーシップなどの世界アクセス戦略は、中低所得国（LMICs）における経口抗ウイルス薬の製造と流通の拡大に役立っています。メディシン・パテント・プールやUNITAIDのような組織は、これまで抗ウイルス療法が十分でなかった地域でもCOVID-19抗ウイルス剤を利用できるようにする上で重要な役割を果たしています。各国政府が抗ウイルス剤の備蓄とパンデミック対策に投資する中、経口抗ウイルス薬はその展開の容易さから調達戦略において優先されています。

経口抗ウイルス治療薬の世界の需要拡大の原動力は？

経口抗ウイルス薬市場の成長は、ウイルス性疾患負担の増加、外来および在宅治療モデルへのシフト、パンデミックへの備えの取り組みが原動力となっています。主な成長要因は、ウイルス発生時のヘルスケア負担と死亡率を軽減する、スケーラブルで早期段階の抗ウイルス介入に対する世界のニーズです。人獣共通感染症ウイルスの出現、抗ウイルス剤耐性の増加、将来のパンデミック（世界的大流行）のリスクにより、各国政府や医療機関は迅速対応の抗ウイルス剤ポートフォリオへの投資を余儀なくされています。

HIV、B型肝炎、C型肝炎、単純ヘルペス感染症などの慢性ウイルス疾患は、低毒性でアドヒアランスを改善しながら長期的なウイルス抑制を可能にする経口抗ウイルス薬に対する持続的な需要を生み出し続けています。一方、遠隔医療、デジタル薬局、分散型臨床試験の成長により、経口抗ウイルス療法の迅速な診断、処方、モニタリングが可能になりつつあります。

研究開発投資の拡大、緊急時の使用に対する規制当局の支援、パンデミックの可能性のあるウイルス病原体を標的とした強力なパイプラインにより、経口抗ウイルス薬市場は力強い拡大の態勢を整えています。これらの治療法は、既存の感染症の治療パラダイムを変革するだけでなく、将来のウイルスの脅威に対する世界ヘルスの強靭性を強化するものでもあります。

セグメント

適応症（ヒト免疫不全ウイルス、肝炎、インフルエンザ、その他の適応症）;販売チャネル（ドラッグストア・小売薬局、病院薬局、オンラインプロバイダー）;薬剤クラス（逆転写酵素阻害薬、プロテアーゼ阻害薬、その他の薬剤クラス別）

調査対象企業の例（注目の44社）

• AbbVie Inc.
• Amneal Pharmaceuticals LLC
• Aurobindo Pharma Ltd.
• BioCryst Pharmaceuticals Inc.
• Bristol-Myers Squibb Co.
• Cipla Ltd.
• Dr. Reddy's Laboratories Ltd.
• Enanta Pharmaceuticals Inc.
• F. Hoffmann-La Roche Ltd.
• Gilead Sciences Inc.
• GlaxoSmithKline plc（GSK）
• Hetero Labs Ltd.
• Johnson & Johnson
• Lupin Pharmaceuticals Ltd.
• Merck & Co., Inc.
• Novartis AG
• Pfizer Inc.
• Shionogi & Co., Ltd.
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd.

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、人為的な売上原価の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

Global Industry Analystsは、世界の主要なチーフ・エコノミスト（1万4,949人）、シンクタンク（62団体）、貿易・産業団体（171団体）の専門家の意見に熱心に従いながら、エコシステムへの影響を評価し、新たな市場の現実に対処しています。あらゆる主要国の専門家やエコノミストが、関税とそれが自国に与える影響についての意見を追跡調査しています。

Global Industry Analystsは、この混乱が今後2-3ヶ月で収束し、新しい世界秩序がより明確に確立されると予想しています。Global Industry Analystsは、これらの開発をリアルタイムで追跡しています。

2025年4月：交渉フェーズ

4月のリリースでは、世界市場全体に対する関税の影響を取り上げ、地域別の市場調整について紹介します。当社の予測は、過去のデータと進化する市場影響要因に基づいています。

2025年7月：最終関税リセット

お客様には、各国間で最終リセットが発表された後、7月に無料アップデート版をお届けします。最終アップデート版には、明確に定義された関税影響分析が組み込まれています。

相互および二国間貿易と関税の影響分析：

アメリカ <>中国<>メキシコ <>カナダ <>EU <>日本<>インド <>その他176カ国

業界をリードするエコノミスト：Global Industry Analystsの知識ベースは、国家、シンクタンク、貿易・産業団体、大企業、そして世界の計量経済状況におけるこの前例のないパラダイムシフトの影響を共有する領域の専門家など、最も影響力のあるチーフエコノミストの厳選されたグループを含む1万4,949人のエコノミストを追跡しています。我々の16,491以上のレポートのほとんどは、マイルストーンに基づくこの2段階のリリーススケジュールを取り入れています。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Oral Antivirals Market to Reach US$39.0 Billion by 2030

The global market for Oral Antivirals estimated at US$35.7 Billion in the year 2024, is expected to reach US$39.0 Billion by 2030, growing at a CAGR of 1.5% over the analysis period 2024-2030. Human Immunodeficiency Virus Indication, one of the segments analyzed in the report, is expected to record a 1.0% CAGR and reach US$18.0 Billion by the end of the analysis period. Growth in the Hepatitis Indication segment is estimated at 2.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$9.7 Billion While China is Forecast to Grow at 2.8% CAGR

The Oral Antivirals market in the U.S. is estimated at US$9.7 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$7.1 Billion by the year 2030 trailing a CAGR of 2.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 0.6% and 1.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 0.8% CAGR.

Global Oral Antivirals Market - Key Trends & Drivers Summarized

Are Oral Antiviral Therapies Reshaping the Landscape of Infectious Disease Management?

Oral antivirals-drugs formulated for oral administration that inhibit the replication of viruses inside host cells-have emerged as a cornerstone of modern antiviral therapy. Unlike injectable antivirals that require healthcare administration, oral formulations provide convenience, scalability, and outpatient suitability-qualities that are critical during public health crises and for chronic viral conditions. From influenza and hepatitis to HIV, herpes, and most recently COVID-19, oral antivirals are demonstrating clinical and commercial success across diverse viral pathogens.

The COVID-19 pandemic served as a global proving ground for oral antivirals, with molecules like molnupiravir and nirmatrelvir/ritonavir (Paxlovid) being deployed at scale to reduce viral load, hospitalization rates, and transmission risk. These treatments highlighted the strategic importance of stockpiling, early intervention, and community-based delivery in pandemic preparedness. The success of these agents is encouraging both pharmaceutical giants and biotech startups to accelerate development pipelines targeting respiratory, neurotropic, and hemorrhagic viruses with oral therapies.

Why Are Broad-Spectrum Agents and Resistance-Proof Mechanisms in High Demand?

With viral mutation posing a constant challenge to therapeutic efficacy, there is a growing demand for broad-spectrum oral antivirals that act on conserved viral targets. Polymerase inhibitors, protease inhibitors, and entry inhibitors are being engineered for cross-viral activity against multiple strains and species. Such drugs reduce the reliance on pathogen-specific diagnostics and simplify treatment regimens-especially in regions with limited laboratory infrastructure.

To mitigate the risk of antiviral resistance, drug developers are designing agents with high genetic barriers to resistance and exploring combination therapies that reduce selective pressure. Host-directed antivirals, which interfere with host pathways essential to viral replication, are gaining traction due to their pan-viral potential. Additionally, prodrug formulations and pharmacokinetic enhancers are being used to improve bioavailability, tissue penetration, and therapeutic window while enabling once-daily oral dosing for chronic conditions like HIV and HBV.

How Are Technology Platforms and Market Access Strategies Expanding the Therapeutic Reach?

The advent of structure-based drug design, AI-driven compound screening, and high-throughput viral assays is accelerating the identification of novel oral antiviral candidates. Pharmaceutical companies are leveraging machine learning and in silico modeling to design molecules with optimal pharmacodynamics and safety profiles. Oral antivirals are also benefiting from advancements in solid dosage form technologies such as nanoparticle carriers, enteric coatings, and sustained-release formulations to enhance absorption and patient compliance.

Global access strategies-including voluntary licensing, tiered pricing, and public-private partnerships-are helping scale up manufacturing and distribution of oral antivirals in low- and middle-income countries (LMICs). Organizations like Medicines Patent Pool and UNITAID are playing a key role in making COVID-19 antivirals accessible across regions previously underserved by antiviral therapy. As governments invest in antiviral stockpiling and pandemic readiness, oral antivirals are being prioritized in procurement strategies due to their ease of deployment.

What’s Driving the Growing Demand for Oral Antiviral Therapeutics Globally?

The growth in the oral antivirals market is driven by rising viral disease burden, the shift toward outpatient and home-based treatment models, and pandemic preparedness initiatives. A primary growth driver is the global need for scalable, early-stage antiviral interventions that reduce healthcare strain and mortality in viral outbreaks. The emergence of zoonotic viruses, increasing antiviral resistance, and the risk of future pandemics are compelling governments and health systems to invest in rapid-response antiviral portfolios.

Chronic viral conditions such as HIV, hepatitis B and C, and herpes simplex infections continue to generate sustained demand for oral antivirals that combine long-term viral suppression with low toxicity and improved adherence. Meanwhile, the growth of telemedicine, digital pharmacies, and decentralized clinical trials is enabling faster diagnosis, prescription, and monitoring of oral antiviral therapy.

With growing R&D investments, regulatory support for emergency use, and a strong pipeline targeting viral pathogens of pandemic potential, the oral antivirals market is poised for robust expansion. These therapies are not only transforming the treatment paradigm for existing infections but also reinforcing global health resilience against future viral threats.

SCOPE OF STUDY:

The report analyzes the Oral Antivirals market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Indication (Human Immunodeficiency Virus, Hepatitis, Influenza, Other Indications); Distribution Channel (Drug Stores & Retail Pharmacies, Hospital Pharmacies, Online Providers); Drug Class (Reverse Transcriptase Inhibitors, Protease Inhibitors, Other Drug Classes)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 44 Featured) -

• AbbVie Inc.
• Amneal Pharmaceuticals LLC
• Aurobindo Pharma Ltd.
• BioCryst Pharmaceuticals Inc.
• Bristol-Myers Squibb Co.
• Cipla Ltd.
• Dr. Reddy's Laboratories Ltd.
• Enanta Pharmaceuticals Inc.
• F. Hoffmann-La Roche Ltd.
• Gilead Sciences Inc.
• GlaxoSmithKline plc (GSK)
• Hetero Labs Ltd.
• Johnson & Johnson
• Lupin Pharmaceuticals Ltd.
• Merck & Co., Inc.
• Novartis AG
• Pfizer Inc.
• Shionogi & Co., Ltd.
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Tariff Impact on Global Supply Chain Patterns
  • Oral Antivirals - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Incidence of Viral Infections Drives Global Demand for Broad-Spectrum Oral Antivirals
  • Expansion of Pandemic Preparedness Programs Throws the Spotlight on Scalable Oral Antiviral Stockpiles
  • OEM Innovation in Nucleoside and Protease Inhibitors Strengthens Pipeline of Small-Molecule Therapies
  • Regulatory Approvals for COVID-19 Oral Antivirals Accelerate Market Acceptance and Infrastructure Investment
  • Growth in Antiviral Use for Influenza, Hepatitis, and Herpes Simplex Supports Therapeutic Portfolio Expansion
  • OEM Partnerships With Academic Institutions Enhance Discovery of Novel Antiviral Compounds
  • Increased Focus on Antiviral Resistance Drives Development of Combination Oral Regimens
  • Emergence of Host-Targeted Antivirals Expands Scope for Long-Term Disease Suppression
  • OEM Investment in Oral Prodrug Technologies Enhances Bioavailability and Dosing Convenience
  • Global Support for Equitable Access to Oral Therapies Promotes Expansion in Low- and Middle-Income Countries
  • Regulatory Incentives for Orphan and Rare Viral Diseases Propel Clinical Development Pipelines
  • Rising Use in Prophylaxis and Post-Exposure Scenarios Strengthens Adoption in High-Risk Populations
  • OEM Focus on Rapid Onboarding and At-Home Treatment Modalities Drives Patient-Centered Drug Design
  • Growth in Direct-to-Patient Telehealth Platforms Supports Remote Prescription and Dispensation of Oral Antivirals
  • OEM Advances in Resistance Profiling and Companion Diagnostics Enable Personalized Antiviral Therapy
  • Expansion of Pediatric and Geriatric Formulations Broadens Age-Specific Treatment Adoption
  • Government Stockpiling for Biodefense and Outbreak Response Enhances Market Stability
  • OEM Emphasis on Thermostable and Shelf-Stable Formulations Facilitates Deployment in Remote Regions
  • Growing Role of AI in Antiviral Molecule Screening Accelerates Drug Discovery Timelines
  • Strategic Licensing and Global Procurement Agreements Drive Competitive Market Dynamics
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Oral Antivirals Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Oral Antivirals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Oral Antivirals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Oral Antivirals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Human Immunodeficiency Virus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Human Immunodeficiency Virus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Human Immunodeficiency Virus by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Hepatitis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Hepatitis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Hepatitis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Influenza by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Influenza by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Influenza by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Other Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Reverse Transcriptase Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Reverse Transcriptase Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Reverse Transcriptase Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Protease Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Protease Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Protease Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Drug Stores & Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Drug Stores & Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Drug Stores & Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Online Providers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Online Providers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 34: World 15-Year Perspective for Online Providers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Oral Antivirals Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 35: USA Recent Past, Current & Future Analysis for Oral Antivirals by Indication - Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 36: USA Historic Review for Oral Antivirals by Indication - Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 37: USA 15-Year Perspective for Oral Antivirals by Indication - Percentage Breakdown of Value Sales for Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications for the Years 2015, 2025 & 2030
  • TABLE 38: USA Recent Past, Current & Future Analysis for Oral Antivirals by Drug Class - Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 39: USA Historic Review for Oral Antivirals by Drug Class - Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 40: USA 15-Year Perspective for Oral Antivirals by Drug Class - Percentage Breakdown of Value Sales for Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors for the Years 2015, 2025 & 2030
  • TABLE 41: USA Recent Past, Current & Future Analysis for Oral Antivirals by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 42: USA Historic Review for Oral Antivirals by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 43: USA 15-Year Perspective for Oral Antivirals by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 44: Canada Recent Past, Current & Future Analysis for Oral Antivirals by Indication - Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 45: Canada Historic Review for Oral Antivirals by Indication - Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 46: Canada 15-Year Perspective for Oral Antivirals by Indication - Percentage Breakdown of Value Sales for Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications for the Years 2015, 2025 & 2030
  • TABLE 47: Canada Recent Past, Current & Future Analysis for Oral Antivirals by Drug Class - Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 48: Canada Historic Review for Oral Antivirals by Drug Class - Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 49: Canada 15-Year Perspective for Oral Antivirals by Drug Class - Percentage Breakdown of Value Sales for Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors for the Years 2015, 2025 & 2030
  • TABLE 50: Canada Recent Past, Current & Future Analysis for Oral Antivirals by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Canada Historic Review for Oral Antivirals by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 52: Canada 15-Year Perspective for Oral Antivirals by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers for the Years 2015, 2025 & 2030
• JAPAN
  • Oral Antivirals Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 53: Japan Recent Past, Current & Future Analysis for Oral Antivirals by Indication - Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Japan Historic Review for Oral Antivirals by Indication - Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 55: Japan 15-Year Perspective for Oral Antivirals by Indication - Percentage Breakdown of Value Sales for Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications for the Years 2015, 2025 & 2030
  • TABLE 56: Japan Recent Past, Current & Future Analysis for Oral Antivirals by Drug Class - Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Japan Historic Review for Oral Antivirals by Drug Class - Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 58: Japan 15-Year Perspective for Oral Antivirals by Drug Class - Percentage Breakdown of Value Sales for Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors for the Years 2015, 2025 & 2030
  • TABLE 59: Japan Recent Past, Current & Future Analysis for Oral Antivirals by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Japan Historic Review for Oral Antivirals by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 61: Japan 15-Year Perspective for Oral Antivirals by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers for the Years 2015, 2025 & 2030
• CHINA
  • Oral Antivirals Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 62: China Recent Past, Current & Future Analysis for Oral Antivirals by Indication - Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: China Historic Review for Oral Antivirals by Indication - Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 64: China 15-Year Perspective for Oral Antivirals by Indication - Percentage Breakdown of Value Sales for Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications for the Years 2015, 2025 & 2030
  • TABLE 65: China Recent Past, Current & Future Analysis for Oral Antivirals by Drug Class - Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: China Historic Review for Oral Antivirals by Drug Class - Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 67: China 15-Year Perspective for Oral Antivirals by Drug Class - Percentage Breakdown of Value Sales for Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors for the Years 2015, 2025 & 2030
  • TABLE 68: China Recent Past, Current & Future Analysis for Oral Antivirals by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: China Historic Review for Oral Antivirals by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 70: China 15-Year Perspective for Oral Antivirals by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers for the Years 2015, 2025 & 2030
• EUROPE
  • Oral Antivirals Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 71: Europe Recent Past, Current & Future Analysis for Oral Antivirals by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 72: Europe Historic Review for Oral Antivirals by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 73: Europe 15-Year Perspective for Oral Antivirals by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 74: Europe Recent Past, Current & Future Analysis for Oral Antivirals by Indication - Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Europe Historic Review for Oral Antivirals by Indication - Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 76: Europe 15-Year Perspective for Oral Antivirals by Indication - Percentage Breakdown of Value Sales for Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications for the Years 2015, 2025 & 2030
  • TABLE 77: Europe Recent Past, Current & Future Analysis for Oral Antivirals by Drug Class - Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Europe Historic Review for Oral Antivirals by Drug Class - Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 79: Europe 15-Year Perspective for Oral Antivirals by Drug Class - Percentage Breakdown of Value Sales for Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors for the Years 2015, 2025 & 2030
  • TABLE 80: Europe Recent Past, Current & Future Analysis for Oral Antivirals by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Europe Historic Review for Oral Antivirals by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 82: Europe 15-Year Perspective for Oral Antivirals by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers for the Years 2015, 2025 & 2030
• FRANCE
  • Oral Antivirals Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 83: France Recent Past, Current & Future Analysis for Oral Antivirals by Indication - Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: France Historic Review for Oral Antivirals by Indication - Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 85: France 15-Year Perspective for Oral Antivirals by Indication - Percentage Breakdown of Value Sales for Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications for the Years 2015, 2025 & 2030
  • TABLE 86: France Recent Past, Current & Future Analysis for Oral Antivirals by Drug Class - Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: France Historic Review for Oral Antivirals by Drug Class - Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 88: France 15-Year Perspective for Oral Antivirals by Drug Class - Percentage Breakdown of Value Sales for Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors for the Years 2015, 2025 & 2030
  • TABLE 89: France Recent Past, Current & Future Analysis for Oral Antivirals by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: France Historic Review for Oral Antivirals by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 91: France 15-Year Perspective for Oral Antivirals by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers for the Years 2015, 2025 & 2030
• GERMANY
  • Oral Antivirals Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 92: Germany Recent Past, Current & Future Analysis for Oral Antivirals by Indication - Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Germany Historic Review for Oral Antivirals by Indication - Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 94: Germany 15-Year Perspective for Oral Antivirals by Indication - Percentage Breakdown of Value Sales for Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications for the Years 2015, 2025 & 2030
  • TABLE 95: Germany Recent Past, Current & Future Analysis for Oral Antivirals by Drug Class - Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Germany Historic Review for Oral Antivirals by Drug Class - Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 97: Germany 15-Year Perspective for Oral Antivirals by Drug Class - Percentage Breakdown of Value Sales for Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors for the Years 2015, 2025 & 2030
  • TABLE 98: Germany Recent Past, Current & Future Analysis for Oral Antivirals by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Germany Historic Review for Oral Antivirals by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 100: Germany 15-Year Perspective for Oral Antivirals by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 101: Italy Recent Past, Current & Future Analysis for Oral Antivirals by Indication - Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Italy Historic Review for Oral Antivirals by Indication - Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 103: Italy 15-Year Perspective for Oral Antivirals by Indication - Percentage Breakdown of Value Sales for Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications for the Years 2015, 2025 & 2030
  • TABLE 104: Italy Recent Past, Current & Future Analysis for Oral Antivirals by Drug Class - Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Italy Historic Review for Oral Antivirals by Drug Class - Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 106: Italy 15-Year Perspective for Oral Antivirals by Drug Class - Percentage Breakdown of Value Sales for Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors for the Years 2015, 2025 & 2030
  • TABLE 107: Italy Recent Past, Current & Future Analysis for Oral Antivirals by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Italy Historic Review for Oral Antivirals by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 109: Italy 15-Year Perspective for Oral Antivirals by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Oral Antivirals Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 110: UK Recent Past, Current & Future Analysis for Oral Antivirals by Indication - Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: UK Historic Review for Oral Antivirals by Indication - Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 112: UK 15-Year Perspective for Oral Antivirals by Indication - Percentage Breakdown of Value Sales for Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications for the Years 2015, 2025 & 2030
  • TABLE 113: UK Recent Past, Current & Future Analysis for Oral Antivirals by Drug Class - Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: UK Historic Review for Oral Antivirals by Drug Class - Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 115: UK 15-Year Perspective for Oral Antivirals by Drug Class - Percentage Breakdown of Value Sales for Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors for the Years 2015, 2025 & 2030
  • TABLE 116: UK Recent Past, Current & Future Analysis for Oral Antivirals by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: UK Historic Review for Oral Antivirals by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 118: UK 15-Year Perspective for Oral Antivirals by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 119: Spain Recent Past, Current & Future Analysis for Oral Antivirals by Indication - Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: Spain Historic Review for Oral Antivirals by Indication - Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 121: Spain 15-Year Perspective for Oral Antivirals by Indication - Percentage Breakdown of Value Sales for Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications for the Years 2015, 2025 & 2030
  • TABLE 122: Spain Recent Past, Current & Future Analysis for Oral Antivirals by Drug Class - Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Spain Historic Review for Oral Antivirals by Drug Class - Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 124: Spain 15-Year Perspective for Oral Antivirals by Drug Class - Percentage Breakdown of Value Sales for Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors for the Years 2015, 2025 & 2030
  • TABLE 125: Spain Recent Past, Current & Future Analysis for Oral Antivirals by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Spain Historic Review for Oral Antivirals by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 127: Spain 15-Year Perspective for Oral Antivirals by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 128: Russia Recent Past, Current & Future Analysis for Oral Antivirals by Indication - Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Russia Historic Review for Oral Antivirals by Indication - Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 130: Russia 15-Year Perspective for Oral Antivirals by Indication - Percentage Breakdown of Value Sales for Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications for the Years 2015, 2025 & 2030
  • TABLE 131: Russia Recent Past, Current & Future Analysis for Oral Antivirals by Drug Class - Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Russia Historic Review for Oral Antivirals by Drug Class - Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 133: Russia 15-Year Perspective for Oral Antivirals by Drug Class - Percentage Breakdown of Value Sales for Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors for the Years 2015, 2025 & 2030
  • TABLE 134: Russia Recent Past, Current & Future Analysis for Oral Antivirals by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Russia Historic Review for Oral Antivirals by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 136: Russia 15-Year Perspective for Oral Antivirals by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Oral Antivirals by Indication - Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Rest of Europe Historic Review for Oral Antivirals by Indication - Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 139: Rest of Europe 15-Year Perspective for Oral Antivirals by Indication - Percentage Breakdown of Value Sales for Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications for the Years 2015, 2025 & 2030
  • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Oral Antivirals by Drug Class - Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Rest of Europe Historic Review for Oral Antivirals by Drug Class - Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 142: Rest of Europe 15-Year Perspective for Oral Antivirals by Drug Class - Percentage Breakdown of Value Sales for Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors for the Years 2015, 2025 & 2030
  • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Oral Antivirals by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Rest of Europe Historic Review for Oral Antivirals by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 145: Rest of Europe 15-Year Perspective for Oral Antivirals by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Oral Antivirals Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Oral Antivirals by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 147: Asia-Pacific Historic Review for Oral Antivirals by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 148: Asia-Pacific 15-Year Perspective for Oral Antivirals by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Oral Antivirals by Indication - Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Asia-Pacific Historic Review for Oral Antivirals by Indication - Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 151: Asia-Pacific 15-Year Perspective for Oral Antivirals by Indication - Percentage Breakdown of Value Sales for Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications for the Years 2015, 2025 & 2030
  • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Oral Antivirals by Drug Class - Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Asia-Pacific Historic Review for Oral Antivirals by Drug Class - Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 154: Asia-Pacific 15-Year Perspective for Oral Antivirals by Drug Class - Percentage Breakdown of Value Sales for Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors for the Years 2015, 2025 & 2030
  • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Oral Antivirals by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Asia-Pacific Historic Review for Oral Antivirals by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 157: Asia-Pacific 15-Year Perspective for Oral Antivirals by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Oral Antivirals Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 158: Australia Recent Past, Current & Future Analysis for Oral Antivirals by Indication - Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Australia Historic Review for Oral Antivirals by Indication - Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 160: Australia 15-Year Perspective for Oral Antivirals by Indication - Percentage Breakdown of Value Sales for Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications for the Years 2015, 2025 & 2030
  • TABLE 161: Australia Recent Past, Current & Future Analysis for Oral Antivirals by Drug Class - Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Australia Historic Review for Oral Antivirals by Drug Class - Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 163: Australia 15-Year Perspective for Oral Antivirals by Drug Class - Percentage Breakdown of Value Sales for Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors for the Years 2015, 2025 & 2030
  • TABLE 164: Australia Recent Past, Current & Future Analysis for Oral Antivirals by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Australia Historic Review for Oral Antivirals by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 166: Australia 15-Year Perspective for Oral Antivirals by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers for the Years 2015, 2025 & 2030
• INDIA
  • Oral Antivirals Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 167: India Recent Past, Current & Future Analysis for Oral Antivirals by Indication - Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: India Historic Review for Oral Antivirals by Indication - Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 169: India 15-Year Perspective for Oral Antivirals by Indication - Percentage Breakdown of Value Sales for Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications for the Years 2015, 2025 & 2030
  • TABLE 170: India Recent Past, Current & Future Analysis for Oral Antivirals by Drug Class - Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: India Historic Review for Oral Antivirals by Drug Class - Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 172: India 15-Year Perspective for Oral Antivirals by Drug Class - Percentage Breakdown of Value Sales for Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors for the Years 2015, 2025 & 2030
  • TABLE 173: India Recent Past, Current & Future Analysis for Oral Antivirals by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: India Historic Review for Oral Antivirals by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 175: India 15-Year Perspective for Oral Antivirals by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 176: South Korea Recent Past, Current & Future Analysis for Oral Antivirals by Indication - Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: South Korea Historic Review for Oral Antivirals by Indication - Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 178: South Korea 15-Year Perspective for Oral Antivirals by Indication - Percentage Breakdown of Value Sales for Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications for the Years 2015, 2025 & 2030
  • TABLE 179: South Korea Recent Past, Current & Future Analysis for Oral Antivirals by Drug Class - Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: South Korea Historic Review for Oral Antivirals by Drug Class - Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 181: South Korea 15-Year Perspective for Oral Antivirals by Drug Class - Percentage Breakdown of Value Sales for Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors for the Years 2015, 2025 & 2030
  • TABLE 182: South Korea Recent Past, Current & Future Analysis for Oral Antivirals by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: South Korea Historic Review for Oral Antivirals by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 184: South Korea 15-Year Perspective for Oral Antivirals by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Oral Antivirals by Indication - Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 186: Rest of Asia-Pacific Historic Review for Oral Antivirals by Indication - Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 187: Rest of Asia-Pacific 15-Year Perspective for Oral Antivirals by Indication - Percentage Breakdown of Value Sales for Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications for the Years 2015, 2025 & 2030
  • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Oral Antivirals by Drug Class - Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Rest of Asia-Pacific Historic Review for Oral Antivirals by Drug Class - Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 190: Rest of Asia-Pacific 15-Year Perspective for Oral Antivirals by Drug Class - Percentage Breakdown of Value Sales for Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors for the Years 2015, 2025 & 2030
  • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Oral Antivirals by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Rest of Asia-Pacific Historic Review for Oral Antivirals by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 193: Rest of Asia-Pacific 15-Year Perspective for Oral Antivirals by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Oral Antivirals Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 194: Latin America Recent Past, Current & Future Analysis for Oral Antivirals by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 195: Latin America Historic Review for Oral Antivirals by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 196: Latin America 15-Year Perspective for Oral Antivirals by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 197: Latin America Recent Past, Current & Future Analysis for Oral Antivirals by Indication - Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Latin America Historic Review for Oral Antivirals by Indication - Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 199: Latin America 15-Year Perspective for Oral Antivirals by Indication - Percentage Breakdown of Value Sales for Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications for the Years 2015, 2025 & 2030
  • TABLE 200: Latin America Recent Past, Current & Future Analysis for Oral Antivirals by Drug Class - Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Latin America Historic Review for Oral Antivirals by Drug Class - Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 202: Latin America 15-Year Perspective for Oral Antivirals by Drug Class - Percentage Breakdown of Value Sales for Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors for the Years 2015, 2025 & 2030
  • TABLE 203: Latin America Recent Past, Current & Future Analysis for Oral Antivirals by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Latin America Historic Review for Oral Antivirals by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 205: Latin America 15-Year Perspective for Oral Antivirals by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 206: Argentina Recent Past, Current & Future Analysis for Oral Antivirals by Indication - Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Argentina Historic Review for Oral Antivirals by Indication - Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 208: Argentina 15-Year Perspective for Oral Antivirals by Indication - Percentage Breakdown of Value Sales for Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications for the Years 2015, 2025 & 2030
  • TABLE 209: Argentina Recent Past, Current & Future Analysis for Oral Antivirals by Drug Class - Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Argentina Historic Review for Oral Antivirals by Drug Class - Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 211: Argentina 15-Year Perspective for Oral Antivirals by Drug Class - Percentage Breakdown of Value Sales for Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors for the Years 2015, 2025 & 2030
  • TABLE 212: Argentina Recent Past, Current & Future Analysis for Oral Antivirals by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Argentina Historic Review for Oral Antivirals by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 214: Argentina 15-Year Perspective for Oral Antivirals by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 215: Brazil Recent Past, Current & Future Analysis for Oral Antivirals by Indication - Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Brazil Historic Review for Oral Antivirals by Indication - Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 217: Brazil 15-Year Perspective for Oral Antivirals by Indication - Percentage Breakdown of Value Sales for Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications for the Years 2015, 2025 & 2030
  • TABLE 218: Brazil Recent Past, Current & Future Analysis for Oral Antivirals by Drug Class - Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Brazil Historic Review for Oral Antivirals by Drug Class - Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 220: Brazil 15-Year Perspective for Oral Antivirals by Drug Class - Percentage Breakdown of Value Sales for Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors for the Years 2015, 2025 & 2030
  • TABLE 221: Brazil Recent Past, Current & Future Analysis for Oral Antivirals by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Brazil Historic Review for Oral Antivirals by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 223: Brazil 15-Year Perspective for Oral Antivirals by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 224: Mexico Recent Past, Current & Future Analysis for Oral Antivirals by Indication - Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Mexico Historic Review for Oral Antivirals by Indication - Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 226: Mexico 15-Year Perspective for Oral Antivirals by Indication - Percentage Breakdown of Value Sales for Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications for the Years 2015, 2025 & 2030
  • TABLE 227: Mexico Recent Past, Current & Future Analysis for Oral Antivirals by Drug Class - Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Mexico Historic Review for Oral Antivirals by Drug Class - Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 229: Mexico 15-Year Perspective for Oral Antivirals by Drug Class - Percentage Breakdown of Value Sales for Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors for the Years 2015, 2025 & 2030
  • TABLE 230: Mexico Recent Past, Current & Future Analysis for Oral Antivirals by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Mexico Historic Review for Oral Antivirals by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 232: Mexico 15-Year Perspective for Oral Antivirals by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Oral Antivirals by Indication - Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Rest of Latin America Historic Review for Oral Antivirals by Indication - Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 235: Rest of Latin America 15-Year Perspective for Oral Antivirals by Indication - Percentage Breakdown of Value Sales for Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications for the Years 2015, 2025 & 2030
  • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Oral Antivirals by Drug Class - Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Rest of Latin America Historic Review for Oral Antivirals by Drug Class - Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 238: Rest of Latin America 15-Year Perspective for Oral Antivirals by Drug Class - Percentage Breakdown of Value Sales for Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors for the Years 2015, 2025 & 2030
  • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Oral Antivirals by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Rest of Latin America Historic Review for Oral Antivirals by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 241: Rest of Latin America 15-Year Perspective for Oral Antivirals by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Oral Antivirals Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 242: Middle East Recent Past, Current & Future Analysis for Oral Antivirals by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 243: Middle East Historic Review for Oral Antivirals by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 244: Middle East 15-Year Perspective for Oral Antivirals by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 245: Middle East Recent Past, Current & Future Analysis for Oral Antivirals by Indication - Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Middle East Historic Review for Oral Antivirals by Indication - Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 247: Middle East 15-Year Perspective for Oral Antivirals by Indication - Percentage Breakdown of Value Sales for Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications for the Years 2015, 2025 & 2030
  • TABLE 248: Middle East Recent Past, Current & Future Analysis for Oral Antivirals by Drug Class - Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Middle East Historic Review for Oral Antivirals by Drug Class - Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 250: Middle East 15-Year Perspective for Oral Antivirals by Drug Class - Percentage Breakdown of Value Sales for Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors for the Years 2015, 2025 & 2030
  • TABLE 251: Middle East Recent Past, Current & Future Analysis for Oral Antivirals by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Middle East Historic Review for Oral Antivirals by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 253: Middle East 15-Year Perspective for Oral Antivirals by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 254: Iran Recent Past, Current & Future Analysis for Oral Antivirals by Indication - Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Iran Historic Review for Oral Antivirals by Indication - Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 256: Iran 15-Year Perspective for Oral Antivirals by Indication - Percentage Breakdown of Value Sales for Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications for the Years 2015, 2025 & 2030
  • TABLE 257: Iran Recent Past, Current & Future Analysis for Oral Antivirals by Drug Class - Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Iran Historic Review for Oral Antivirals by Drug Class - Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 259: Iran 15-Year Perspective for Oral Antivirals by Drug Class - Percentage Breakdown of Value Sales for Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors for the Years 2015, 2025 & 2030
  • TABLE 260: Iran Recent Past, Current & Future Analysis for Oral Antivirals by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Iran Historic Review for Oral Antivirals by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 262: Iran 15-Year Perspective for Oral Antivirals by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 263: Israel Recent Past, Current & Future Analysis for Oral Antivirals by Indication - Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Israel Historic Review for Oral Antivirals by Indication - Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 265: Israel 15-Year Perspective for Oral Antivirals by Indication - Percentage Breakdown of Value Sales for Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications for the Years 2015, 2025 & 2030
  • TABLE 266: Israel Recent Past, Current & Future Analysis for Oral Antivirals by Drug Class - Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Israel Historic Review for Oral Antivirals by Drug Class - Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 268: Israel 15-Year Perspective for Oral Antivirals by Drug Class - Percentage Breakdown of Value Sales for Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors for the Years 2015, 2025 & 2030
  • TABLE 269: Israel Recent Past, Current & Future Analysis for Oral Antivirals by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Israel Historic Review for Oral Antivirals by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 271: Israel 15-Year Perspective for Oral Antivirals by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Oral Antivirals by Indication - Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Saudi Arabia Historic Review for Oral Antivirals by Indication - Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 274: Saudi Arabia 15-Year Perspective for Oral Antivirals by Indication - Percentage Breakdown of Value Sales for Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications for the Years 2015, 2025 & 2030
  • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Oral Antivirals by Drug Class - Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Saudi Arabia Historic Review for Oral Antivirals by Drug Class - Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 277: Saudi Arabia 15-Year Perspective for Oral Antivirals by Drug Class - Percentage Breakdown of Value Sales for Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors for the Years 2015, 2025 & 2030
  • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Oral Antivirals by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Saudi Arabia Historic Review for Oral Antivirals by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 280: Saudi Arabia 15-Year Perspective for Oral Antivirals by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 281: UAE Recent Past, Current & Future Analysis for Oral Antivirals by Indication - Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 282: UAE Historic Review for Oral Antivirals by Indication - Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 283: UAE 15-Year Perspective for Oral Antivirals by Indication - Percentage Breakdown of Value Sales for Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications for the Years 2015, 2025 & 2030
  • TABLE 284: UAE Recent Past, Current & Future Analysis for Oral Antivirals by Drug Class - Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 285: UAE Historic Review for Oral Antivirals by Drug Class - Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 286: UAE 15-Year Perspective for Oral Antivirals by Drug Class - Percentage Breakdown of Value Sales for Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors for the Years 2015, 2025 & 2030
  • TABLE 287: UAE Recent Past, Current & Future Analysis for Oral Antivirals by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 288: UAE Historic Review for Oral Antivirals by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 289: UAE 15-Year Perspective for Oral Antivirals by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Oral Antivirals by Indication - Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 291: Rest of Middle East Historic Review for Oral Antivirals by Indication - Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 292: Rest of Middle East 15-Year Perspective for Oral Antivirals by Indication - Percentage Breakdown of Value Sales for Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications for the Years 2015, 2025 & 2030
  • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Oral Antivirals by Drug Class - Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Rest of Middle East Historic Review for Oral Antivirals by Drug Class - Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 295: Rest of Middle East 15-Year Perspective for Oral Antivirals by Drug Class - Percentage Breakdown of Value Sales for Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors for the Years 2015, 2025 & 2030
  • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Oral Antivirals by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Rest of Middle East Historic Review for Oral Antivirals by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 298: Rest of Middle East 15-Year Perspective for Oral Antivirals by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers for the Years 2015, 2025 & 2030
• AFRICA
  • Oral Antivirals Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 299: Africa Recent Past, Current & Future Analysis for Oral Antivirals by Indication - Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Africa Historic Review for Oral Antivirals by Indication - Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 301: Africa 15-Year Perspective for Oral Antivirals by Indication - Percentage Breakdown of Value Sales for Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications for the Years 2015, 2025 & 2030
  • TABLE 302: Africa Recent Past, Current & Future Analysis for Oral Antivirals by Drug Class - Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Africa Historic Review for Oral Antivirals by Drug Class - Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 304: Africa 15-Year Perspective for Oral Antivirals by Drug Class - Percentage Breakdown of Value Sales for Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors for the Years 2015, 2025 & 2030
  • TABLE 305: Africa Recent Past, Current & Future Analysis for Oral Antivirals by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Africa Historic Review for Oral Antivirals by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 307: Africa 15-Year Perspective for Oral Antivirals by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers for the Years 2015, 2025 & 2030

IV. COMPETITION